"Apolipoprotein A-I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE.
| Descriptor ID |
D016632
|
| MeSH Number(s) |
D10.532.091.200.100 D12.776.070.400.200.100 D12.776.521.120.200.100
|
| Concept/Terms |
Apolipoprotein A-I- Apolipoprotein A-I
- Apolipoprotein A I
- Apo A-I
- Apo A1
- Apolipoprotein AI
- ApoA-1
- ApoA-I
- Apolipoprotein A-1
- Apolipoprotein A 1
- Apolipoprotein A1
- Apo A-1
- Apo AI
Pro-Apolipoprotein A-I- Pro-Apolipoprotein A-I
- Pro Apolipoprotein A I
- Pro-Apo A-I
- Pro Apo A I
- Proapolipoprotein AI
- Apolipoprotein AI Propeptide
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein A-I".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein A-I".
This graph shows the total number of publications written about "Apolipoprotein A-I" by people in this website by year, and whether "Apolipoprotein A-I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Apolipoprotein A-I" by people in Profiles.
-
LAL (Lysosomal Acid Lipase) Promotes Reverse Cholesterol Transport In Vitro and In Vivo. Arterioscler Thromb Vasc Biol. 2018 05; 38(5):1191-1201.
-
ATP-Binding Cassette Transporter A1 Deficiency in Human Induced Pluripotent Stem Cell-Derived Hepatocytes Abrogates HDL Biogenesis and Enhances Triglyceride Secretion. EBioMedicine. 2017 Apr; 18:139-145.
-
Charge-transfer interactions induce surface dependent conformational changes in apolipoprotein biocorona. Biointerphases. 2017 03 07; 12(2):02D402.
-
HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes. Diabetes Care. 2014 Aug; 37(8):2351-8.
-
Serum apolipoproteins are associated with systemic and retinal microvascular function in people with diabetes. Diabetes. 2012 Jul; 61(7):1785-92.
-
Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages. Arterioscler Thromb Vasc Biol. 2011 May; 31(5):1192-200.
-
Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther. 2010; 12(3):R93.
-
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2010 Apr; 30(4):766-72.
-
Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared with men. Diabetes. 2008 Dec; 57(12):3289-96.
-
Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res. 2008 Apr; 49(4):847-55.